Clinical considerations with the use of antiplatelet therapy in patients undergoing percutaneous coronary intervention

Clinical Cardiology

Volumn 31, Issue 3 SUUPL. 1, 2008, Pages

  Braunwald, Eugene ^a   Angiolillo, Dominick ^b   Bates, Eric ^c   Berger, Peter B ^d   Bhatt, Deepak ^e   Cannon, Christopher P ^a   Furman, Mark I ^f   Gurbel, Paul ^g   Michelson, Alan D ^h   Peterson, Eric ⁱ   Wiviott, Stephen ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d GEISINGER MEDICAL CENTER   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f South Shore Hospital   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndromes

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; PACLITAXEL; PLACEBO; RAPAMYCIN; THIENOPYRIDINE DERIVATIVE; TROPONIN;

ACUTE CORONARY SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; CONTROL GROUP; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; DRUG MECHANISM; DRUG WITHDRAWAL; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; LONG TERM CARE; MAINTENANCE THERAPY; PERCUTANEOUS CORONARY INTERVENTION; THROMBOSIS PREVENTION; TREATMENT WITHDRAWAL;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD PLATELETS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GUIDELINE ADHERENCE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRACTICE GUIDELINES AS TOPIC; STENTS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 41249099499     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20359     Document Type: Conference Paper

References (29)

1. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107 2908-2913
2. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, et al.: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251
3. Steinhubl SR, Berger LPB, Mann JT III, Fry ETA, DeLago A, et al.: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002;288:2411-2420
4. Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, et al.: Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation 2005;111:2099-2106
5. Montalescot G, Sideris G, Meuleman C, Bal-dit-Sollier C, Lellouche N, et al.: A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006;48:931-938
6. Kastrati A, von Beckerath N, Joost A, Pogatsa-Murray G, Gorchakova O, et al.: Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation 2004;110:1916-1919
7. vou Beckerath N, Kastrati A, Wieczorek A, Pogatsa-Murray G, Sibbing D, et al.: A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75 mg of clopidogrel for 30 days. Eur Heart J 2007;28:1814-1819
8. Ferreira IA, Mocking AIM, Feijge MAH, Gorter G, van Haeften TW, et al.: Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006;26:417-422
9. Ferroni P, Basili S, Falco A, Davi G: Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004;1:1282-1291
10. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, et al.: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435
11. Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, et al.: Randomized comparison of high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007;115:708-716
12. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, et al.: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717
13. Mehta SR: Clopidogrel in non-ST segment elevation acute coronary syndromes. Eur Heart 2006;8:G25-G30
14. Steinhubl SR, Berger PB, Brennan DM, Topol EJ, For the CREDO investigators: Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006;47:939-943
15. Kandzari DE, Berger PB, Kastrati A, Steinhubl SR, Mehilli J, et al.: Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004;44:2133-2136
16. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, for the American College of Cardiology/American Heart Association Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2007;50:e1-e157
17. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, et al.: Clopidogrel loading with eptifibatide to arrest the reactiviety of platelets: results of the clopidogrel loading with eptifibatide to arrest the reactivity of platelets (CLEAR PLATELETS) study. Circulation 2005;111:1153-1159
18. Gurbel PA, Bliden KP, Tantry US: Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. J Am Coll Cardiol 2006;48: 2186-2191
19. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, et al.: Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006;119: 1056-1061
20. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, et al.: late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591
21. Eisenstein EL, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, et al.: Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168
22. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, et al.: International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189
23. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, et al.: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006;113(7):e166-e286
24. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Saugiori JM, et al.: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130
25. Park DW, Park SW, Park KH, Lee BK, Kim YH, et al.: Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol 2006;98:352-256
26. Jeremias A, Sylvia B, Bridges J, Kirtane AJ, Bigelow B, et al.: Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 2004;109:1930-1932
27. Spertus JA, Kettelkamp R, Vance C, Decker C, Jones PG, et al.: Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006;113:2803-2809
28. Grilles CL, Bonow RO, Casey DE Jr, Gardner TJ, Lockhart PB, et al.: Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation 2007;115:813-818
29. Curfman GD, Morrissey S, Jarcho JA, Drazen JM: Drug-eluting coronary stents - promise and uncertainty. N Engl J Med 2007;356:1059-1060